Literature DB >> 17291854

Parental smoking impairs vaccine responses in children with atopic genotypes.

Gareth Baynam1, Siew-Kim Khoo, Julie Rowe, Guicheng Zhang, Ingrid Laing, Catherine Hayden, Merci Kusel, Nick DeKlerk, Peter Sly, Jack Goldblatt, Patrick Holt, Peter LeSouef.   

Abstract

BACKGROUND: Gene-environment interactions play central roles in controlling postnatal maturation of immune function, but their effects on infant vaccine responses are unknown. Genetic variants associated with atopy and the environmental factor of exposure to parental smoking (PS) of tobacco independently alter immune responses.
OBJECTIVE: We sought to investigate the hypothesis that genetic variants associated with atopy and their interaction with PS influence infant vaccine responsiveness.
METHODS: In 200 infants with parental atopic history, relationships were sought between polymorphisms in the IL-4, IL-4 receptor alpha (IL-4Ralpha), and IL-13 genes; PS; and immune responses to diphtheria/tetanus vaccination.
RESULTS: Analyses stratified by PS unmasked negative associations between atopic alleles of these genes and vaccine outcomes. The most consistent involved the IL-4Ralpha 551 QR/QQ genotypes, which were associated with reduced IgG levels (P = .02) and T-cell responses (IFN-gamma, P = .002; IL-10, P = .01; 1L-13, P = .01; IL-5, P = .06) to tetanus toxoid and parallel reductions in polyclonal T-cell responses and innate immune responses in PS-exposed infants.
CONCLUSION: PS potentiates suppressive effects of variants in immune response genes in children. These effects are not observed in the absence of this exposure. Ultimately, this finding might have implications for infant vaccination in countries with high smoking rates. It might also have broader implications in relation to environmental toxicology because it demonstrates specific mechanisms through which the developing immune system might be differentially sensitive to low-level toxicant exposures. CLINICAL IMPLICATIONS: PS interacts with genes associated with atopy to impair vaccine responses. These interactions might have vaccine design and public health implications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17291854     DOI: 10.1016/j.jaci.2006.09.018

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  5 in total

Review 1.  Genetic studies of African populations: an overview on disease susceptibility and response to vaccines and therapeutics.

Authors:  Giorgio Sirugo; Branwen J Hennig; Adebowale A Adeyemo; Alice Matimba; Melanie J Newport; Muntaser E Ibrahim; Kelli K Ryckman; Alessandra Tacconelli; Renato Mariani-Costantini; Giuseppe Novelli; Himla Soodyall; Charles N Rotimi; Raj S Ramesar; Sarah A Tishkoff; Scott M Williams
Journal:  Hum Genet       Date:  2008-05-30       Impact factor: 4.132

2.  Negative effect of smoking on the performance of the QuantiFERON TB gold in tube test.

Authors:  Martine G Aabye; Thomas Stig Hermansen; Morten Ruhwald; George Praygod; Daniel Faurholt-Jepsen; Kidola Jeremiah; Maria Faurholt-Jepsen; Nyagosya Range; Henrik Friis; John Changalucha; Aase B Andersen; Pernille Ravn
Journal:  BMC Infect Dis       Date:  2012-12-27       Impact factor: 3.090

3.  Differences of plasma IL-1 and TNF-α in healthy Chinese Population.

Authors:  Jintao Yuan; Lan Wang; Yijin Lin; Jianhong Chen; Jianghong Hu
Journal:  Open Med (Wars)       Date:  2015-06-09

4.  IgG responses to Pneumococcal and Haemophilus influenzae protein antigens are not impaired in children with a history of recurrent acute otitis media.

Authors:  Selma P Wiertsema; Karli J Corscadden; Eva N Mowe; Guicheng Zhang; Shyan Vijayasekaran; Harvey L Coates; Timothy J Mitchell; Wayne R Thomas; Peter C Richmond; Lea-Ann S Kirkham
Journal:  PLoS One       Date:  2012-11-12       Impact factor: 3.240

Review 5.  Developmental Immunotoxicity, Perinatal Programming, and Noncommunicable Diseases: Focus on Human Studies.

Authors:  Rodney R Dietert
Journal:  Adv Med       Date:  2014-01-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.